Tag: licensing
-
New Drug Shown to Reduce Depressive Behaviors
A new type of treatment for depression that works differently from most other anti-depressive drugs was shown in lab mice to reduce depression-like behaviors.
-
Start-Up Formed to Develop Non-Opioid Pain Drugs
A new enterprise is being formed to develop non-addictive drugs for chronic pain that use different biochemical processes than opioid pain relievers.
-
RNA Meds Companies Partner on Human, Animal Vaccines
Synthetic Genomics Inc. and Arcturus Therapeutics Inc. are collaborating on longer-lasting and more robust RNA therapies and vaccines for humans and animals.
-
Univ. Lab, Company Broaden Bacterial Vaccine Impact
Researchers from University at Buffalo and a campus spin-off enterprise devised a way to expand the scope of anti-bacterial vaccines, as shown in tests with lab animals.
-
Lilly, CureVac Partner on RNA Cancer Drugs in $1.8B Deal
Drug maker Eli Lilly and Company and biotechnology company CureVac AG agreed to develop a series of cancer immunotherapies based on CureVac’s messenger RNA technology.
-
Univ. Spin-Off Reports Cancer Immunotherapy Advance
A highly targeted synthetic antibody, developed by a university spin-off enterprise, was shown to destroy human breast cancer cells grafted in lab mice.
-
Roche, Biotech to Discover New Antibiotics
A biotechnology company that discovers new drugs through detailed genomic analysis is partnering with drug maker Roche to find new treatments for bacterial infections that resist current antibiotics.
-
Biotech Licenses Gene Editing for Autoimmune Disorders
A company developing therapies with gene editing technologies is acquiring a new form of gene editing on T-cells in the immune system to treat autoimmune diseases.
-
Geisinger, Pharmas Partner on Diabetes Model
An alliance between the Geisinger Health System and two pharmaceutical companies is developing a computer model to predict long-term health risks of patients with type 2 diabetes.
-
Neuro Disease Start-Up Gains $30M in Early Funds
A start-up enterprise developing treatments for several neurological diseases that the company says are triggered by a common destructive protein, is raising $30 million its first venture financing round.